Pertuzumab: Humanized anti-HER2 monoclonal antibody her dimerization inhibitor oncolytic

Drugs of the Future

Volumn 33, Issue 2, 2008, Pages 123-130

  Langdon, Simon P ^a   Mullen, Peter ^a   Faratian, Dana ^a   Harrison, David J ^a   Cameron, David A ^b   Hasmann, Max ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NIHR Cancer Research Network   (United Kingdom)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; ARRY 543; BEVACIZUMAB; BIBW 2992; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; NERATINIB; PACLITAXEL; PELITINIB; PERTUZUMAB; PLACEBO; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; FATIGUE; HEAD AND NECK CANCER; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; RASH; VOMITING;

EID: 41549088729     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.02.1176440     Document Type: Article

References (46)

1. Yarden, Y., Sliwkowski, M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2): 127-37.
2. Bublil, E.M., Yarden, Y. The EGF receptor family: Spear-heading a merger of signalling and therapeutics. Curr Opin Cell Biol 2007, 19(2): 124-34.
3. Hynes, N.E., Lane, H.A. ErbB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005, 5(5): 341-54.
4. Franklin, M.C., Carey, K.D., Vajdos, F.F., Leahy, D.J., de Vos, A.M., Sliwkowski, M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5(4): 317-28.
5. Moasser, M.M. The oncogene HER2: Its signalling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26(45): 6469-87.
6. Graus-Porta, D., Beerli, R.R., Daly, J.M., Hynes, N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors is a mediator of lateral signalling. EMBO J 1997, 16(7): 1647-55.
7. Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W. Jr., Leahy, D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421(6924): 756-60.
8. Alimandi, M., Romano, A., Curia, M.C. et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinoma cells. Oncogene 1995, 10(9): 1813-21.
9. Wallasch, C., Weiss, F.U., Niederfellner, G., Jallal, B., Issing, W., Ullrich, A. Heregulin-dependent regulation of HER2/neu oncogenic signalling by heterodimerization with HER3. EMBO J 1995, 14(17): 4267-75.
10. Moasser, M.M. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007, 26(46): 6577-92.
11. Agus, D.B., Akita, R.W., Fox, W.D. et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2(2): 127-37.
12. Badache, A., Hynes, N.E. A new therapeutic antibody masks erbB2 to its partners. Cancer Cell 2004, 5(4): 299-301.
13. Adams, C.W., Allison, D.E., Flagella, K. et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006, 55(6): 717-27.
14. Fendly, B.M., Winget, M., Hudziak, R.M., Lipari, M.T., Napier, M.A., Ullrich, A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990, 50(5): 1550-8.
15. Lewis, G.D., Lofgren, J.A., McMurtrey, A.E., Nuijens, A., Fendly, B.M., Bauer, K.D., Sliwkowski, M.X. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996, 56(6): 1457-65.
16. Schroff, R.W., Foon, K.A., Beatty, S.M., Oldham, R.K., Morgan, A.C. Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985, 45(2): 879-85.
17. Mullen, P., Cameron, D.A., Hasmann, M., Smyth, J.F., Langdon, S.P. Sensitivity to pertuzumab (2C4) in ovarian cancer models: Cross-talk with estrogen receptor signaling. Mol Cancer Ther 2007, 6(1): 93-100.
18. Takai, N., Jain, A., Kawamata, N. et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005, 104(12): 2701-8.
19. Friess, T., Scheuer, W., Hasmann, M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005, 11(14): 5300-9.
20. Jackson, J.G., St. Clair, P., Sliwkowski, M.X., Brattain, M.G. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004, 64(7): 2601-9.
21. Le, X., Mao, W., Lu, Y., Mills, G.B., Bast, R.C. Jr. HER2 antibodies pertuzumab and trastuzumab differ in their effect on cell signaling and growth inhibition in breast cancer cells. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 3836.
22. Bossenmaier, B., Hasmann, M., Koll, H. et al. Presence of HER2 / HER3 heterodimers predicts antitumour effects of pertuzumab (Omnitarg) in different human xenograft models. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 5342.
23. Nahta, R., Hung, M.C., Esteva, F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004, 64(7): 2343-6.
24. Friess, M., Scheuer, W., Hasmann, M. Antitumour activity of trastuzumab combined with various agents targeting HER-family receptors in HER2-positive xenografts progressing under trastuzumab monotherapy. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 651.
25. Friess, T., Scheuer, W., Hasmann, M. Superior anti-tumor activity after combination treatment with pertuzumab and trastuzumab against NSCLC and breast cancer xenograft tumours. Ann Oncol [31st Eur Soc Med Oncol (ESMO) (Sept 29-Oct 3, Istanbul) 2006, 17(Suppl. 9): Abst 96PD.
26. Arpino, G., Gutierrez, C., Weiss, H. et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007, 99(9): 694-705.
27. Hasmann, M., Juchem, R., Scheuer, W., Friess, T. Pertuzumab (Omnitarg) potentiates antitumor effects on NSCLC xenografts when combined with cytotoxic chemotherapeutic agents. 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst B213.
28. Scheuer, W., Friess, T., Hasmann, M. Enhanced antitumour effect by combination of HER-targeting antibodies with beva cizumab in a human breast cancer xenograft model. Eur J Cancer - Suppl 2006, 4(12): Abst 213.
29. Agus, D.B., Gordon, M.S., Taylor, C. et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005, 23(11): 2534-43.
30. Gordon, M.S., Matei, D., Aghajanian, C. et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006, 24(26): 4324-32.
31. Cortes, J., Baselga, J., Kellokumpu-Lehtinen, P. et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3068.
32. Ng, C.M., Lum, B.L., Gimenez, V., Kelsey, S., Allison, D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006, 23(6): 1275-84.
33. Malik, M.A., Totpal, K., Balter, I. et al. Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd ed): Abst 773.
34. Amler, L.C., Eberhard, D., Mackey, H. et. al. Identification of a predictive expression pattern for phosphorylated HER2 and clinical activity of pertuzumab (OmnitargTM), a HER dimerization inhibitor in tumours from ovarian cancer patients. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4497.
35. de Bono, J.S., Bellmunt, J., Attard, G. et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007, 25(3): 257-62.
36. Agus, D.B., Sweeney, C.J., Morris, M.J. et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007, 25(6): 675-81.
37. Johnson, B.E., Janne, P.A. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res 2006, 12(14, Pt. 2): 4436s-40s.
38. Tovey, S.M., Dunne, B., Witton, C.J., Forsyth, A., Cooke, T.G., Bartlett, J.M.S. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005, 11(13): 4835-42.
39. Tovey, S.M., Witton, C.J., Bartlett, J.M.S., Stanton, P.D., Reeves, J.R., Cooke, T.G. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004, 6(3): R246-51.
40. Ellis, I.O., Bartlett, J., Dowsett, M. et al. Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004, 57(3): 233-7.
41. Makhija, S., Glenn, D., Ueland, F. et al. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 5507.
42. Baselga, J., Cameron, D., Miles, D. et al. Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 1004.
43. Portera, C.C., Walshe, J.M., Denduluri, N. et al. A report of cardiac events in a phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 1028.
44. A study of pertuzumab in combination with Herceptin in patients with HER2 positive breast cancer (NCT00545688). ClinicalTrials.gov Web Site, January 22, 2008.
45. A study to evaluate pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated Her2-positive metastatic breast cancer (CLEOPATRA) (NCT00567190). ClinicalTrials.gov Web site, January 22, 2008.
46. Pertuzumab, cetuximab, and irinotecan in treating patients with previously treated locally advanced or metastatic colorectal cancer (NCT00551421). ClinicalTrials.gov Web site, January 22, 2008.